公开(公告)号：US20220362256A1

公开(公告)日：2022-11-17

申请号：US17771152

申请日：2020-10-22

Applicant: Amgen Inc.

Inventor： Vishnu CHINTALGATTU ,  Aditya A. GOEL ,  Christina TEKLE

IPC: A61K31/5377 ,  A61K31/197 ,  A61K31/437 ,  A61K31/519 ,  A61K45/06 ,  A61P9/12

Abstract: Provided herein are methods of treating, inhibiting, reducing, or ameliorating cardiovascular adverse events in a patient caused by administration of carfilzomib by administering to the patient at least one of a soluble guanylyl cyclase (sGC) activator, a PDE5 inhibitor, p38 inhibitor, and/or MAPKAPK-2 inhibitor.

公开(公告)号：US20220089689A1

公开(公告)日：2022-03-24

申请号：US17491715

申请日：2021-10-01

Applicant: AMGEN INC.

Inventor： Jason C. O'NEILL ,  Randal R. KETCHEM ,  TaeWeon LEE ,  Vishnu CHINTALGATTU ,  Jennitte LeAnn STEVENS

IPC: C07K14/81

Abstract: There are disclosed TIMP-3 muteins, variants and derivatives, nucleic acids encoding them, and methods of making and using them.